CLAIMS
1. A MIC-1 compound comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pi lower than 6.5.
2. Compound according to claim 1, wherein the compound is a homodimer and consists of between 218-296, 224-296 or 230-296 amino acid residues.
3. Compound according to any of the preceding claims, wherein said extension is in the range of 3-36, 3-30, 3-24, 3-12, 4-36, 4-30, , 4-24, 4-12, 5-36, 5-30, 5-24, 5-12, 6-36, 6-30, 6-24, 6-12, 7-36, 7-30, 7-24, 7-12, 8-36, 8-30, 8-24, 8-12, 30-36, 32-36, 30-34, or 30-32 amino acid residues in length.
4. Compound according to any of the preceding claims, wherein the extension has surplus of acidic amino acid residues (Aspartic acid and Glutamic acid) of at least 3, 4, 5 or 6 compared to the number of basic amino acid residues (Lysine, Arginine and Histidine)
5. Compound according to any of the preceding claims, wherein the extension is composed of amino acid residues selected among the group consisting of A, E, G, P, S, T, Q, and D and wherein said extension comprises at least three E and/or D amino acid residues.
6. Compound according to claim 5, wherein the extension comprises 6 Ser, 4 Pro, 4 Gly, 4Thr, 4Glu and 2 Ala.
7. Compound according to any of claims 1-6, wherein the extension comprises one or more of the following sequences
SPAGSP (SEQ ID NO:4), TSESAT(SEQ ID NO:5), TSTEPE (SEQ ID NO:6), SEPATS (SEQ ID NO:7), TSTEEG (SEQ ID NO:8), PESGPG (SEQ ID NO:9),

SGSAPG (SEQ ID NO: 10), GSETPG (SEQ ID NO: 11),
SEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO: 12), SEPATSGSETPGTSESATPESGPG (SEQ ID NO: 13), SEPATSGSETPGTSTEPESGSAPG (SEQ ID NO: 14), SEPATSGSETPGSPAGSPTSTEEGSPAGSP (SEQ ID NO: 15), SEPATSGSETPGTSESATPESGPGSPAGSP (SEQ ID NO: 16), SEPATSGSETPGTSTEPESGSAPGSPAGSP (SEQ ID NO: 17), SEPATSGSETPGSPAGSPTSTEEGTSESAT (SEQ ID NO: 18), SEPATSGSETPGTSESATPESGPGTSESAT (SEQ ID NO: 19), SEPATSGSETPGTSTEPESGSAPGTSESAT (SEQ ID NO:20), SEPATSGSETPGSPAGSPTSTEEGTSTEPE (SEQ ID NO:21), SEPATSGSETPGTSESATPESGPGTSTEPE (SEQ ID NO:22), SEPATSGSETPGTSTEPESGSAPGTSTEPE (SEQ ID NO:23), SEPATSGSETPGSPAGSPTSTEEGSEPATS (SEQ ID NO:24), SEPATSGSETPGTSESATPESGPGSEPATS (SEQ ID NO:25), SEPATSGSETPGTSTEPESGSAPGSEPATS (SEQ ID NO:26), SEPATSGSETPGSPAGSPTSTEEGTSTEEG (SEQ ID NO:27), SEPATSGSETPGTSESATPESGPGTSTEEG (SEQ ID NO:28), SEPATSGSETPGTSTEPESGSAPGTSTEEG (SEQ ID NO:29), SEPATSGSETPGSPAGSPTSTEEGPESGPG (SEQ ID NO:30), SEPATSGSETPGTSESATPESGPGPESGPG (SEQ ID NO:31), SEPATSGSETPGTSTEPESGSAPGPESGPG (SEQ ID NO:32), SEPATSGSETPGSPAGSPTSTEEGSGSAPG (SEQ ID NO:33), SEPATSGSETPGTSESATPESGPGSGSAPG (SEQ ID NO:34), SEPATSGSETPGTSTEPESGSAPGSGSAPG (SEQ ID NO:35), SEPATSGSETPGSPAGSPTSTEEGGSETPG (SEQ ID NO:36), SEPATSGSETPGTSESATPESGPGGSETPG (SEQ ID NO:37), SEPATSGSETPGTSTEPESGSAPGGSETPG (SEQ ID NO:38), SEPATSGSETPGTSESATPESGPGTSTEPS (SEQ ID NO:70), SEPATSGSETPGTSESATPESGPGTSTEPSEG (SEQ ID NO:71), SEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG (SEQ ID NO:39), SEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEG (SEQ ID NO:40), SEPATSGSETPGSPAGSPTSTEEGTSTEPESGSAPG (SEQ ID NO:41), SEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG (SEQ ID NO:42), SEPATSGSETPGTSESATPESGPGTSESATPESGPG (SEQ ID NO:43),

SEPATSGSETPGTSESATPESGPGTSTEPESGSAPG (SEQ ID NO:44), SEPATSGSETPGTSESATPESGPGSEPATSGSETPG (SEQ ID NO:45), SEPATSGSETPGTSTEPESGSAPGSPAGSPTSTEEG (SEQ ID NO:46), SEPATSGSETPGTSTEPESGSAPGTSESATPESGPG (SEQ ID NO:47), SEPATSGSETPGTSTEPESGSAPGTSTEPESGSAPG (SEQ ID NO:48), SEPATSGSETPGTSTEPESGSAPGSEPATSGSETPG (SEQ ID NO:49), SEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEG (SEQ ID NO:50), SEPATSGSETPGSEPATSGSETPGTSESATPESGPG (SEQ ID NO:51), SEPATSGSETPGSEPATSGSETPGTSTEPESGSAPG (SEQ ID NO:52), SEPATSGSETPGSEPATSGSETPGSEPATSGSETPG (SEQ ID NO:53), GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO: 138) and SSSG (SEQ ID NO: 139).
8. Compound according to any of claims 1-6, wherein the extension comprises one or
more of the following sequences
GEPS (SEQ ID NO:118),
GPSE (SEQ ID NO:119),
GPES (SEQ ID NO: 120),
GSPE (SEQ ID NO:121),
GSEP (SEQ ID NO: 122),
GEPSGEPSGEPSGEPSGEPS (SEQ ID NO: 140),
GPSEGPSEGPSEGPSEGPSE (SEQ ID NO: 141),
GPESGPESGPESGPESGPES (SEQ ID NO: 142),
GSPEGSPEGSPEGSPEGSPE (SEQ ID NO: 143),
GSEPGSEPGSEPGSEPGSE (SEQ ID NO: 144),
GEPQ (SEQ ID NO: 123), GEQP (SEQ ID NO: 124),
GPEQ (SEQ ID NO: 125), GPQE (SEQ ID NO: 126),
GQEP (SEQ ID NO: 127), GQPE (SEQ ID NO: 128),
GEPQGEPQGEPQGEPQGEPQ (SEQ ID NO: 145),
GEQPGEQPGEQPGEQPGEQP (SEQ ID NO: 146),
GPEQGPEQGPEQGPEQGPEQ (SEQ ID NO: 147),
GPQEGPQEGPQEGPQEGPQE (SEQ ID NO: 148),
GQEPGQEPGQEPGQEPGQEP (SEQ ID NO: 149),
GQPEGQPEGQPEGQPEGQPE (SEQ ID NO: 150),

GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO: 138) and SSSG (SEQ ID NO: 139).
9. Compound according to any of claims 1-6, wherein the extension comprises one or
more of the following sequences
PEDEETPEQE (SEQ ID NO: 129), PDEGTEEETE (SEQ ID NO: 130), PAAEEEDDPD (SEQ ID NO:131), AEPDEDPQSED (SEQ ID NO: 132), AEPDEDPQSE (SEQ ID NO: 133), AEPEEQEED (SEQ ID NO: 134), AEPEEQEE (SEQ ID NO: 135), AEEAEEAEEAEEAEE (SEQ ID NO: 151), GGGS (SEQ ID NO: 136), GSGS (SEQ ID NO: 137), GGSS (SEQ ID NO: 138) and SSSG (SEQ ID NO: 139).
10. Compound according to any one of the preceding claims, wherein the MIC-1 polypeptide displays at least 85%, 90%, 95% or 98% sequence identity to MIC-1 of SEQ ID NO:l.
11. Compound according to any one of the preceding claims wherein the MIC-1 polypeptide comprise one or more of the following substitutions N3E, P11E, H18E, R21E, A30E, A47E, R53E, A54E, M57E, M57L, H66E, R67E, L68E, K69E, A75E, A81E, P85E, M86L, Q90E, T92E, L105E and K107E compared to MIC-1 of SEQ ID NO: 1.
12. Compound according to any one of the preceding claims wherein the MIC-1 polypeptide comprise a deletion of the first three residues (MIC-1-A1-3) or a deletion of N3 (des-N3) compared to MIC-1 of SEQ ID NO:l.
13. A MIC-1 compound comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein the compound comprises an amino acid sequence according to SEQ ID NO: 100, 104, 106, 107, 108, 109, 111, 112, 113, 114, 115, 116, 117 or 164.

14. Compound according to any one of claims 1-13, wherein the compound has a solubility of 0.5, 1.0, 5.0, 10, 30 or 50 mg/ml at pH 8.0 in a Tris buffer system.
15. Compound according to any one of claims 1-14 for use in the prevention and/or treatment of a metabolic disorder, wherein the metabolic disorder is obesity, diabetes, cardiovascular like dyslipidaemia, arteriosclerosis, steatohepatitis, or diabetic nephropathy.